Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

velopment for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity," "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >/= 30 kg/m2), or overweight patients (BMI >/= 27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retr
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... NEW YORK , May 6, 2015 /PRNewswire/ ... patient activation and patient-reported outcomes for chronic pain, ... report released by The Bravewell Collaborative ... by the Patients Receiving Integrative Medicine Interventions Effectiveness ... medicine. Using data from PRIMIER ...
(Date:5/6/2015)... May 6, 2015 Saint-Gobain has ... manufacture of filtration products, mainly for the life sciences ... filters manufactured in a state-of-the-art plant in ... sold across the globe and will bolster the range ... This acquisition is fully in line with the ...
(Date:5/6/2015)... 2015 Fibich, Leebron, Copeland, Briggs & Josephson ... has been reached to resolve lawsuits involving individuals who ... Actos - manufactured by Takeda Pharmaceuticals - has been ... Several of the firm,s attorneys were instrumental in the ... Tommy Fibich - Founding Partner of Fibich, Leebron, ...
Breaking Medicine Technology:Integrative Medicine has Positive Impact on Patient Activation, Chronic Pain, Depression 2Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2Takeda Agrees to $2.4 Billion Settlement for Actos Bladder Cancer Lawsuits 2
... Ontario, May 15, 2012 LifeLearn, Inc. announced ... Distinction for multimedia educational programs that the company ... and Novartis Animal Health (Novartis) during 2011. These ... teach scientific principles to healthcare staff. ...
... May 15, 2012 Reportlinker.com ... research report is available in ... Global ... Marketing Spend and Sales Strategies ...
Cached Medicine Technology:LifeLearn wins awards for three multimedia education programs 2Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 2Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 3Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 4Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 5Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 6Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 7Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 8Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 9Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 10Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 11Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 12Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 13Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 14Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 15Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 16Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 17Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 18
(Date:5/6/2015)... Miami, FL (PRWEB) May 06, 2015 Qushanna ... baby outside a nearby drug treatment center in Florida while ... on May 4th. New surveillance tapes released by CBS4’s ... 7am, without her baby. Doby’s child is around one year ... baby crying and shivering outside was not named. The residents ...
(Date:5/6/2015)... 06, 2015 Prime Pacific Health ... excited to announce a new series of universal, ... industry’s carbon footprint while improving treatment efficacy and ... Eco-Flex™, the world’s first waste hose designed ... for hydrotherapists,” claims the company’s president, Mr. Delmar ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 “ SideChef ” was ... a look at the latest and coolest applications on the market ... and technology expert, conducted the app review and shared with viewers ... in the day when to be a good navigator people had ... out and now everyone is a master navigator. Well what if ...
(Date:5/6/2015)... May 06, 2015 vcfo, a specialized ... IT and operational support to optimize business performance and ... Jack Lynch and Michael Scheaffer. Both Lynch and Scheaffer ... leadership experience. , “We are delighted to add ... vcfo CEO. “Leveraging their background in financial management and ...
(Date:5/6/2015)... TX (PRWEB) May 06, 2015 ... 1,000 user mark after launching in mid-February. The company ... candidates who have previous experience in the industry. Likewise, ... profession. , According to Kyle Johnson, CTO, unique traffic ... to the first month: "Each new job posting brings ...
Breaking Medicine News(10 mins):Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:An Application to Guide Users through Recipes Was Featured on NewsWatch Television 2Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2
... An overactive BAALC gene in acute leukemia cells identifies ... therapy. This study discovered why the gene is often ... help guide therapy in these patients. COLUMBUS, Ohio ... for overactivating a gene linked to poor treatment response in ...
... should be a standard practice of care for pediatric ... growth status and improve treatment, according to a new ... "Not only is bone age helpful in predicting ... bone age is necessary to correctly interpret a patient,s ...
... System has launched the UCLA Face Transplantation Program, the first ... and one of only a handful in the nation. ... to persons who have suffered the devastating loss of their ... associate professor of surgery at the David Geffen School of ...
... work in mice suggested that the immune system is involved ... Researchers have now shown for the first time that this ... College of Medicine and Dentistry, University of Exeter with colleagues ... in Italy screened the expression levels of thousands of genes ...
... Goodwin HealthDay Reporter , THURSDAY, May 24 ... before age 3, most children with autism are diagnosed ... autism in America shows. More than half of ... at least one psychotropic medicine -- including stimulants, anti-anxiety ...
... Reporter , THURSDAY, May 24 (HealthDay News) -- Preeclampsia, a ... predispose offspring to high blood pressure in childhood and young ... life, these children have distinct cardiovascular risk factors that may ... British researchers said. "A pregnancy complicated by preeclampsia is ...
Cached Medicine News:Health News:Inherited DNA change explains overactive leukemia gene 2Health News:Routine care for Crohn's disease in children should include measurement of bone age 2Health News:Routine care for Crohn's disease in children should include measurement of bone age 3Health News:UCLA launches first face transplantation program in western US 2Health News:UCLA launches first face transplantation program in western US 3Health News:Autism Often Not Diagnosed Until Age 5 or Older: U.S. Report 2Health News:Autism Often Not Diagnosed Until Age 5 or Older: U.S. Report 3Health News:High Blood Pressure in Pregnancy May Threaten Kids' Heart Health 2Health News:High Blood Pressure in Pregnancy May Threaten Kids' Heart Health 3
Gendron ophthalmic eye surgery stretcher....
... Membraneblue is a dye developed to ... visualize the I.L.M. and E.R.M.'s. By injecting ... intraocular membranes are stained without diluting the ... under air, the blue stained membranes can ...
Rhex-ID (Trypan Blue 0.8 mg)....
... color monitor produces superb ... icons for easier identification ... choices for measurement. Allows ... smaller pupils than conventional ...
Medicine Products: